Therapeutic strategies such as CD47–signal regulatory protein alpha (SIRPα) blockade and Mer tyrosine kinase/Axl receptor tyrosine kinase (MerTK/Axl) agonists have already entered early‐phase clinical trials [27], showing promising benefits in cancer immunotherapy, atherosclerosis (AS), and tissue repair. This evidence concerns the gene SIRPA and cancer.